Shelley A. Hartman
Directeur Général chez Aegle Therapeutics Corp.
Profil
Shelley A.
Hartman currently works at Aegle Therapeutics Corp., as Chairman & Chief Executive Officer from 2020 and Seraxis, Inc., as Director from 2021.
Ms. Hartman also formerly worked at GMP Cos., Inc., as Chairman, President & Chief Executive Officer from 2004 to 2009, LifeSync Corp., as Chairman, President & Chief Executive Officer, and LifeSync Holdings, Inc., as Chairman from 2010 to 2012.
Ms. Hartman received her undergraduate degree from Wellesley College.
Postes actifs de Shelley A. Hartman
| Sociétés | Poste | Début |
|---|---|---|
Aegle Therapeutics Corp.
 Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | Directeur Général | 01/08/2014 |
Seraxis, Inc.
 Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Directeur/Membre du Conseil | 01/06/2021 |
Anciens postes connus de Shelley A. Hartman
| Sociétés | Poste | Fin |
|---|---|---|
GMP Cos., Inc.
 GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | Directeur Général | 28/12/2009 |
LifeSync Holdings, Inc.
 LifeSync Holdings, Inc. Medical SpecialtiesHealth Technology LifeSync Holdings, Inc. operates as a holding company with interest in medical devices. The firm is a manufacturer and distributor of the LifeSync Wireless ECG System. This system is a wireless ECG transmission device used by hospitals in conjunction with their existing patient monitoring equipment to for patient safety and hospital productivity. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL. | Directeur Général | - |
LifeSync Corp.
 LifeSync Corp. Medical SpecialtiesHealth Technology LifeSync Corp. engages in the development, marketing, and sale clean disposable electrocardiogram technologies. Its products are lifesync wireless ECG system, and disposable leadwear a wireless electrocardiogram data communication system appropriate for use in hospital and outpatient. The company was founded in 2000 and is headquartered in Coral Springs, FL. | President | 13/01/2014 |
Formation de Shelley A. Hartman
| Wellesley College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
GMP Cos., Inc.
GMP Cos., Inc. Pharmaceuticals: MajorHealth Technology GMP Cos., Inc. develops pharmaceuticals, diagnostic products, and medical devices. The firm is also working on treatments for diabetes, glaucoma, and spinal cord injuries. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL | Health Technology |
LifeSync Corp.
LifeSync Corp. Medical SpecialtiesHealth Technology LifeSync Corp. engages in the development, marketing, and sale clean disposable electrocardiogram technologies. Its products are lifesync wireless ECG system, and disposable leadwear a wireless electrocardiogram data communication system appropriate for use in hospital and outpatient. The company was founded in 2000 and is headquartered in Coral Springs, FL. | Health Technology |
LifeSync Holdings, Inc.
LifeSync Holdings, Inc. Medical SpecialtiesHealth Technology LifeSync Holdings, Inc. operates as a holding company with interest in medical devices. The firm is a manufacturer and distributor of the LifeSync Wireless ECG System. This system is a wireless ECG transmission device used by hospitals in conjunction with their existing patient monitoring equipment to for patient safety and hospital productivity. The company was founded in 1999 and is headquartered in Fort Lauderdale, FL. | Health Technology |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | Health Technology |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Health Technology |